Clinical Trial Update: Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss [Phase 1, Phase 2]

View source ↗

Summary

The document provides an update on a Phase 1/2 clinical trial assessing the safety and tolerability of TNG456 alone and with abemaciclib in patients with MTAP-l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Abemaciclib (abemaciclib)
• TNG456

Snippet

Sponsor: Tango Therapeutics, Inc. | Conditions: Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme | Phase 1, Phase 2 | Status: RECRUITING